Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020

SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
April 15, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase...
April 08, 2020 07:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218

SAN FRANCISCO, April 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
April 06, 2020 08:01 ET | Source: Vir Biotechnology, Inc.; GlaxoSmithKline plc

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaksPromising antibody candidates for SARS-CoV-2 to be accelerated into...
March 26, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
March 25, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

- Multiple antibodies identified that neutralize SARS-CoV-2- Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq:...
March 12, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB) for the development and...
March 11, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a research collaboration agreement with the National Institutes of Health (NIH) and the...
March 10, 2020 20:24 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Present at Barclays Global Healthcare Conference

SAN FRANCISCO, March 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious...
February 25, 2020 08:30 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing...